Q2 FY2026 · ended Jun 30, 2026 · Revenue $88,000, -89.5% YoY · Filed Aug 10, 2026
Orchestra BioMed Holdings, Inc. (OBIO) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $88,000 and a net loss of $23.8 million. Free cash flow was -$19.6 million. As of Jun 30, 2026 it held $117.1 million in cash and investments and $1.3 million in total debt.
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- OBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Hope, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1814114
- Former names
- Health Sciences Acquisitions Corp 2 (until Jan 26, 2023)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $88,000 | $110,000 | $30.9M | $861,000 | $836,000 |
| Operating income | -$22.4M | -$22.1M | $6.8M | -$20.3M | -$19.3M |
| Net income | -$23.8M | -$20.7M | $6.2M | -$20.8M | -$19.4M |
| Diluted EPS | -$0.38 | -$0.33 | $0.10 | -$0.40 | -$0.50 |
| Operating cash flow | -$19.3M | -$22.2M | -$2.3M | -$14.6M | -$15.5M |
| Free cash flow | -$19.6M | -$22.4M | -$2.3M | -$14.9M | -$15.6M |
| Total assets | $115.7M | $100.7M | $114.9M | $104.8M | $42.8M |
| Total liabilities | $86.3M | $49.7M | $51.5M | $61.1M | $42.5M |
| Stockholders' equity | $19.3M | $41.2M | $53.6M | $43.7M | $295,000 |
| Cash and investments | $117.1M | $97.8M | $111.4M | $99.9M | $35.2M |
| Total debt | $1.3M | $16.5M | $16.7M | $16.8M | $17.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2026 | Jun 23, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| ARS | Annual report to shareholders | Apr 29, 2026 | Dec 31, 2025 |
All 412 Orchestra BioMed Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.